Medical Science Liaisons (MSLs) are vital to the success of every company. They provide physicians and other healthcare providers with the information and data necessary to ensure that medicines are utilized effectively and safely, they serve as scientific peers and resource … Read More »

Changes in Research (CIRs) come in various forms: protocol amendments, administrative letters, notes to file, safety reports, study committee reports, recruitment plans and unanticipated problems. In this whitepaper we discuss how to assess whether an event meets the guideli … Read More »

There is a distinct difference between outstanding patient support programs and less effective programs. A defining characteristic of successful programs is the level of cross-functional collaboration. By following the six strategies in this white paper, pharmaceutical compa … Read More »

The development and commercialization of novel biopharmaceutical products in recent years has continued to offer more safe and efficacious treatment options for patients across therapeutic areas. While a good proportion of the world’s transformative drug development and earl … Read More »

The type of digital health solutions needed to address the range of challenges faced by pharma companies fall increasingly into the classification of Software as a Medical Device (SaMD). In this whitepaper, experts from S3 Connected Health, Servier, and other leaders in the … Read More »

Mycoplasma is a common cell culture contaminant. Due to its small size, Mycoplasma cannot be detected by standard light microscopy. In addition, Mycoplasma is gram negative and therefore resistant to beta-lactam antibiotics routinely used in cell culture. When manufacturing … Read More »

Whether the focus is endpoint adjudication, aggregate data monitoring or safety assessment, the clinical and device development industry clearly understands the value of establishing expert scientific committees to provide oversight on study data. These expert committee asse … Read More »

As the last year has shown, the life sciences industry has reached a new era in drug discovery, where new medicines can rapidly be brought to market safely and effectively under the right conditions. Clinical data has become one of the most powerful assets for life sciences  … Read More »

Before 2020, most study training provided to clinical research sites relied heavily on monitors doing training at initiation visits, and web-based on-demand training was a novel concept used by only a few forward-thinking sponsors. When the COVID-19 pandemic hit, web-based o … Read More »

Paying participants for the essential role that they play in clinical trials is important, but the amount given, and how it is paid, require careful consideration. Appropriately compensating clinical trial participants lessens the financial burden placed on them by participa … Read More »

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic … Read More »

If identifying and including patients is one of the biggest hurdles of a clinical trial, how does access to 100 million patients sound? This white paper shares how a robust patient database is one critical key that impacts multiple facets of a trial, leading to more successf … Read More »

The biggest challenge facing clinical research today is the need to gather, analyze, and report data. To collect patient data more efficiently, the industry has turned to electronic patient-reported outcome (ePRO) tools, which allow patients to enter data themselves, most of … Read More »

Since the end of the pharmaceutical industry’s “blockbuster era” and the beginning of its “specialty product era”, drug makers have used the term “hub services” to describe the often ponderous process of  ranting patients access to critical medications. While the term itself … Read More »

Discover what you can do today to firmly establish your competitive advantage – to avoid being relegated to the sidelines. Will 2021 allow us to bid farewell to COVID-19? Whether we can eradicate this terrible virus or not, many of its impacts will persist. To assist Sponsor … Read More »

Targeted expertise when and where you need it: WCG Clinical Research Coordinators help equip sites to navigate the “new normal.”

As the market landscape relative to co-pay assistance programs continues to evolve, it is important for biopharmaceutical manufacturers to have a practical strategy in place.  This white paper provides valuable insight into planning for 2021 and beyond. TrialCard Incorporate … Read More »

The defining medium of our age, social media has revolutionized the way we communicate, learn about the world, and organize ourselves into communities. For doctors and other HCPs, social media presents an unprecedented opportunity for engagement and collaboration that is sha … Read More »

A deer in the headlights. That’s an easy way to describe most sales leaders right now, as they formulate how they’re going to implement new “virtual selling” sales frameworks with their formerly “press the flesh” sales teams. But really – a year ago – if you’d suggested to m … Read More »

As COVID-19 continues to disrupt clinical research, the consequences are poised to be devastating for sponsors, physicians, patients, and worldwide health. Elligo Health Research® is uniquely situated and experienced to support the continuation of effective clinical research … Read More »

The disconnect between clinical research and medical care has become increasingly burdensome, especially in the wake of the COVID-19 pandemic. As clinical research sponsors continually seek ways to accelerate their trials while maintaining safety and quality, technology rema … Read More »

Infectious disease “challenge” studies, in which healthy participants are deliberately infected with pathogens to investigate the cause, prevention, and treatment of infectious diseases, hold great potential for delivering high-quality data about new interventions. Infectiou … Read More »

Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. The biggest challenge facing clinical research today is the need to gather, analyze, and report data. To collect patient data more efficiently, researchers are increasingly explorin … Read More »

Affordability programs, like co-pay programs, are highly effective at helping patients initiate therapy by reducing cost barriers. While they also improve fill rates incrementally, affordability programs only address the financial barriers to non-adherence without tackling t … Read More »

Susan  Abedi shares how AI can be a positive disruptor for diagnosis – how to take advantage of  its potential and engage effectively with HCPs and patients to shorten the time to diagnosis. She also covers how AI can raise awareness of the clinical journey. There is also a … Read More »

The world of medical claims data can be extremely complex. With over 100,000 ICD-10 diagnosis and CPT procedure codes currently in use, to wade through de-identified claims data often rests solely on the expertise of those who can confidently navigate vast amounts of big dat … Read More »

View this informative infographic containing numerous statistics about influenza in the U.S.

To help you manage effectively through the intricacies of 340B, Manatt Health has developed a 50-state survey on 340B, analyzing how states reimburse 340B covered entities and contract pharmacies for 340B drugs, and the steps states are taking to avoid duplicate discounts. D … Read More »

“Behavioral science” is becoming a buzzword for pharma. Why? Because behavior is a barrier to meeting brand objectives. This barrier could be in the form of a patient’s adherence, a patient’s reluctance to start a new therapy, or even a healthcare provider’s clinical inertia … Read More »

Over the years, studies have been conducted to ascertain the cost of research and development (“R&D”) required to bring a new drug to market. Experts disagree on the exact amount, but the consensus is that the figure is in the hundreds of millions to over a billion dolla … Read More »